Basic Stats
| CIK | 1335103 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Protea Biosciences Group Inc
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| December 5, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2017 (December 1, 2017) Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Inc |
|
| December 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2017 (November 27, 2017) Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of In |
|
| November 14, 2017 |
PRGB / Protea Biosciences Group Inc NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-51474 CUSIP Number 74365B109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For period ended: September 30, 2017 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tr |
|
| November 13, 2017 |
November 7, 2017 letter of termination of license agreements from The George Washington University. Exhibit 3.1 THE GEORGE WASHINGTON UNIVERSITY WASHINGTON, DC Office of the Executive Vice President and Treasurer November 7, 2017 Protea Biosciences Group, Inc. Sent via Email and Federal Express Courier ATTN: Leo Harris, Director URGENT 1311 Pineview Drive Morgantown, WV 26506 Harris36@myactv .net cc: Compass Advisory Partners, LLC cc: Stephen A. Weiss, Esq. 306 Fourth Avenue, Suite 701 CKR Law, |
|
| November 13, 2017 |
8-K 1 tv4793518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2017 (November 7, 2017) Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or |
|
| November 13, 2017 |
Exhibit 3.2 Kirk B. Burkley, Esq. [email protected] | (412) 456-8108 November 9, 2017 VIA ELECTRONIC MAIL Protea Biosciences Group, Inc. Protea Biosciences, Inc. c/o Christopher P. Schueller, Esquire Buchanan Ingersoll & Rooney, PC One Oxford Centre 301 Grant Street, 20th Floor Pittsburgh, PA 15219-1410 RE: Summit Resources, Inc. / Promissory Note and Loan Agreement Our File Number: 1943-W |
|
| October 26, 2017 |
Form of Pledge Agreement between Registrant and Summit. EX-3.4 5 tv477834ex3-4.htm EXHIBIT 3.4 Exhibit 3.4 STOCK PLEDGE AND SECURITY AGREEMENT THIS STOCK PLEDGE AND SECURITY AGREEMENT (“Agreement”) is made and entered into this day of October, 2017 (the “Effective Date”), by and among PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (the “Pledgor”), and SUMMIT RESOURCES, INC., a West Virginia corporation (the “Lender”), and is joined, accepted an |
|
| October 26, 2017 |
Promissory Note and Loan Agreement between Protea Biosciences, Inc. and Summit Resources, Inc. EX-3.1 2 tv477834ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 PROMISSORY NOTE AND LOAN AGREEMENT Principal Amount: $2,226,173.26 Date of Note: October 19, 2017 Maturity Date: November 18, 2017 THIS PROMISSORY NOTE AND LOAN AGREEMENT (this “Note”) is entered into and effective as of the date first set forth above (the “Effective Date”), by and between PROTEA BIOSCIENCES, INC., a Delaware corporation having an |
|
| October 26, 2017 |
Engagement agreement between the Registrant and Compass Advisory Partners, LLC. EX-3.5 6 tv477834ex3-5.htm EXHIBIT 3.5 Exhibit 3.5 COMPASS ADVISORY PARTNERS, LLC Management CONSULTING ½ INVESTMENT Banking www.CompassAdvisoryPartners.com Nicholas W. Arrington Managing Partner 306 FOURTH AVENUE - SUITE 701 (o) 412.697.2631 PITTSBURGH, PENNSYLVANIA 15222 (c) 412.654.6543 October 20th 2017 Mr. Stephen Turner Chairman and CEO Protea Biosciences Group, Inc. 1311 Pineview Drive Suit |
|
| October 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2017 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 26, 2017 |
Form of Guaranty of Summit Note by Protea Biosciences Group, Inc. EX-3.2 3 tv477834ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 AGREEMENT OF GUARANTY AND SURETYSHIP In order to induce SUMMIT RESOURCES, INC., a West Virginia corporation, and its successors and/or assigns (the “Lender”) to make a loan in a principal amount of Two Million Two Hundred Twenty-Six Thousand One Hundred Seventy-Three and 26/100 Dollars ($2,226,173.26) (the “Loan”) to PROTEA BIOSCIENCES, INC., a De |
|
| October 26, 2017 |
Form of Security Agreement between Protea Biosciences, Inc. and Summit. Exhibit 3.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (together with all exhibits and schedules hereto and all extensions, renewals, amendments, substitutions and replacements hereto and hereof, the ?Security Agreement?), is entered into and effective as of the day of , 2017 (the "Effective Date"), by and between PROTEA BIOSCIENCES, INC., a Delaware corporation having an address at 1311 Pineview |
|
| October 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 16, 2017 (October 13, 2017) Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Inc |
|
| October 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 3, 2017 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 29, 2017 |
Protea Biosciences Group 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2017 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 29, 2017 |
A Revolution In Oncology Medicine Exhibit 99.1 A Revolution In Oncology Medicine 2 Molecular Information is the ultimate ?big data? Trillions of cells in the human body continuously produce billions of biologically - active molecules that define our health and our disease Image of a tumor within a lung Source: PhRMA 2014 Industry Profile, Alkinhibitors. com Safe Harbor Statement - This presentation contains "forward - looking stat |
|
| September 11, 2017 |
Protea Biosciences Group PRE 14A PRE 14A 1 v474900pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Ad |
|
| August 29, 2017 |
As filed with the Securities and Exchange Commission on August 29, 2017 Registration No. |
|
| August 25, 2017 |
EX-3.2 3 v474090ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT (this “Guaranty”), dated as of August , 2017, by PROTEA BIOSCIENCES, INC., a Delaware corporation (the “Guarantor”) in favor of SUMMIT RESOURCES, INC. a West Virginia corporation (the “Lender”), or its registered assigns. PREAMBLE A. Reference is made to that certain $500,000 Promissory Note (the “Note”) d |
|
| August 25, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 v4740908k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 25, 2017 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of |
|
| August 25, 2017 |
EX-3.1 2 v474090ex3-1.htm EXHIBIT 3.1 Exhibit no. 3.1 PROMISSORY NOTE Effective Date: As of August , 2017 U.S. up to $500,000 FOR VALUE RECEIVED, PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (“Borrower” or the “Company”), having any address at 1311 Pineview Drive, Morgantown, West Virginia 26506, promises to pay to the order of SUMMIT RESOURCES, INC., a West Virginia corporation, having |
|
| August 25, 2017 |
PROTEA BIOSCIENCES GROUP, INC. 1311 Pineview Drive, Morgantown, West Virginia 26505 Exhibit 3.4 PROTEA BIOSCIENCES GROUP, INC. 1311 Pineview Drive, Morgantown, West Virginia 26505 August 25, 2017 PPLL PARTNERS, LLC 1732 1st Avenue, Suite 22878, New York, NY 10128 Attn.: James Ahearn -and- SUMMIT RESOURCES, INC. 303 Middle Collison Road, Mount Lookout, West Virginia 26678 Attn: Stephen Antoline, President Gentlemen: Reference is made to the following securities issued by the Compa |
|
| August 25, 2017 |
PROTEA BIOSCIENCES GROUP, INC. TO PURCHASE COMMON STOCK OF THE COMPANY Exhibit 3.3 THIS WARRANT AND THE SECURITIES UNDERLYING THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS AND THE RULES AND REGULATIONS THER |
|
| August 18, 2017 |
PRGB / Protea Biosciences Group Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51474 Protea Bio |
|
| August 14, 2017 |
Protea Biosciences Group FORM 12B-25 NT 10-Q 1 v473206nt10q.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-51474 CUSIP Number 74365B109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For period ended: June 30, 2017 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ T |
|
| June 28, 2017 |
8-K 1 v4698868k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2017 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of In |
|
| May 19, 2017 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 03:34 PM 04/25/2017 FILED 03:34 PM 04/25/2017 SR 20172790022 - File Number 3974950 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF PROTEA BIOSCIENCES GROUP, INC. (a Delaware corporation) The undersigned, Stephen Turner, hereby certifies that: 1. He is the Chief Executive Officer of Protea Bioscience |
|
| May 19, 2017 |
Protea Biosciences Group FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51474 Protea Bi |
|
| May 15, 2017 |
Protea Biosciences Group NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-51474 CUSIP Number 74365B109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: March 31, 2017 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| April 24, 2017 |
SUMMIT RESOURCES, INC. 303 Middle Collison Road, Mount Lookout, West Virginia 26678 Exhibit 3.7 SUMMIT RESOURCES, INC. 303 Middle Collison Road, Mount Lookout, West Virginia 26678 April 20, 2017 Protea Biosciences Group, Inc. and Protea Biosciences, Inc. 1311 Pineview Drive, Morgantown, West Virginia 26506 Gentlemen: Reference is made to the $1,750,000 principal amount senior secured convertible note, dated April 3, 2017 (the “Summit Note”) issued by Protea Biosciences Group, Inc |
|
| April 24, 2017 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2017 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 24, 2017 |
PROTEA BIOSCIENCES GROUP, INC. TO PURCHASE COMMON STOCK OF THE COMPANY Exhibit 3.4 Exhibit A to Senior Secured Convertible Note THIS WARRANT AND THE SECURITIES UNDERLYING THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH SECURITIES ACT, ANY APPLICABLE STATE SECUR |
|
| April 24, 2017 |
Exhibit 3.5 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the ?Agreement?), dated April 17, 2017, but deemed to be effective as of March 31, 2017 (the ?Effective Date?), is made by and between PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (?Company?), and GRQ CONSULTANTS, INC. 401(k) (?GRQ? or ?Holder?), as a holder of a 10% OID senior secured promissory note of the Company in $720,000 orig |
|
| April 24, 2017 |
SENIOR SECURED CONVERTIBLE PROMISSORY NOTE Exhibit 3.1 SENIOR SECURED CONVERTIBLE PROMISSORY NOTE Effective Date: As of April 3, 2017 U.S. $1,750,000.00 FOR VALUE RECEIVED, PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (“Borrower” or the “Company”), having any address at 1311 Pineview Drive, Morgantown, West Virginia 26506, promises to pay to the order of SUMMIT RESOURCES, INC., a West Virginia corporation, having an address at 30 |
|
| April 24, 2017 |
RESTATED SENIOR SECURED CONVERTIBLE PROMISSORY NOTE EX-3.6 7 v464938ex3-6.htm EXHIBIT 3.6 Exhibit 3.6 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD |
|
| April 24, 2017 |
EX-3.3 4 v464938ex3-3.htm EXHIBIT 3.3 Exhibit 3.3 Exhibit B to Senior Secured Convertible Note SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of April , 2017 (as amended, supplemented or otherwise modified from time to time in accordance with the provisions hereof, this "Agreement"), made by and among (A) PROTEA BIOSCIENCES GROUP, INC.., a Delaware corporation (“PRGB” or the “Company”), (B) |
|
| April 24, 2017 |
EX-3.2 3 v464938ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 Exhibit C to Senior Secured Convertible Note GUARANTY AGREEMENT THIS GUARANTY AGREEMENT (this “Guaranty”), dated as of April , 2017, by PROTEA BIOSCIENCES, INC., a Delaware corporation (the “Guarantor”) in favor of SUMMIT RESOURCES, INC. a West Virginia corporation (the “Lender”), or its registered assigns. PREAMBLE A. Reference is made to that cer |
|
| April 14, 2017 |
Protea Biosciences Group FORM 10-K (Annual Report) United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended December 31, 2016 or ? transition report under section 13 Or 15(d) of the securities exchange act of 1934 For the transition period from to Commission file number 000-51474 PROTEA BIOSCIENCES GROUP, INC. (Exact |
|
| April 14, 2017 |
Exhibit 10.141 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| April 14, 2017 |
Exhibit 10.142 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”), dated as of March ], 2017, is made by and between PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (“Company”), and the undersigned signatory hereto (“Holder”), as a holder of the Units of Common Stock and Warrants (as defined below) in the Company’s 2013 Offering (as defined below). INTRODUCTION: This Agreement is |
|
| April 14, 2017 |
PROTEA BIOSCIENCES GROUP, INC. HOLDING CORP. CONVERTIBLE PROMISSORY NOTE Exhibit 10.138 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN A |
|
| April 14, 2017 |
EX-21.1 10 v462304ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARY OF THE COMPANY Protea Biosciences, Inc. (Delaware Corporation) |
|
| April 14, 2017 |
Exhibit 10.137 DEBT CONVERSION AGREEMENT THIS DEBT CONVERSION AGREEMENT (this “Agreement”) made as of the date set forth on the signature page hereto (the “Agreement Date”) between PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (the “Company”), and the Person who has executed this Agreement under the designation “Investor” on the signature page of this Agreement (the “Investor”). W I T N E |
|
| April 14, 2017 |
EX-10.143 8 v462304ex10-143.htm EXHIBIT 10.143 Exhibit 10.143 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”), dated as of March ], 2017, is made by and between PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (“Company”), and the undersigned signatory hereto (“Holder”), as a holder of the Units of Common Stock and Warrants (as defined below) in the Company’s 2016-17 Offering (a |
|
| April 14, 2017 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.106 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR |
|
| April 14, 2017 |
FORM OF CLASS B COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. EX-10.140 5 v462304ex10-140.htm EXHIBIT 10.140 Exhibit 10.140 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFER |
|
| April 14, 2017 |
Exhibit 10.144 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the “Company”), and the undersigned (the “Investor”). WITNESSETH: WHEREAS, in 2016, the Company conducted a private offering (the “Offering”) of 20% original issue discount unsecured convertible debentures (the “Debentu |
|
| April 5, 2017 |
FORM OF CLASS A COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 3.3 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI |
|
| April 5, 2017 |
FORM OF CLASS B COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 3.4 EXHIBIT D NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI |
|
| April 5, 2017 |
Exhibit 3.1 AMENDED AND RESTATED CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM Protea Biosciences Group, Inc. Up to $5,000,000 500 Units of Securities Consisting of Shares of Common Stock and Warrants to Purchase Common Stock This Amended and Restated Confidential Private Placement Memorandum together with all exhibits and documents incorporated by reference (the ?Memorandum?) relates to an offering ( |
|
| April 5, 2017 |
Exhibit 3.2 Exhibit A SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the “Company”), and the undersigned (the “Subscriber”). WITNESSETH: WHEREAS, the Company is conducting a private offering (the “Offering”) of up a minimum of $500,000 and up to a maximum of $5,000,000 of units |
|
| April 5, 2017 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2017 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2017 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 31, 2017 |
Protea Biosciences Group NT 10-K NT 10-K 1 v463177nt10-k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-51474 CUSIP Number 74365B109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: December 31, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ |
|
| March 28, 2017 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits 8-K 1 v4626978k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2017 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of |
|
| March 28, 2017 |
EX-3.1 2 v462697ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 DEBT CONVERSION AGREEMENT THIS DEBT CONVERSION AGREEMENT (this “Agreement”) made as of the date set forth on the signature page hereto (the “Agreement Date”) between PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (the “Company”), and the Person who has executed this Agreement under the designation “Investor” on the signature page of this Ag |
|
| March 2, 2017 |
Protea Biosciences Group DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Mate |
|
| February 23, 2017 |
Protea Biosciences Group PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 2) (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials |
|
| February 21, 2017 |
Protea Biosciences Group PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials |
|
| February 15, 2017 |
CORRESP 1 filename1.htm PROTEA BIOSCIENCES GROUP, INC. Protea Biosciences Group, Inc. 1311 Pineview Drive, Suite 501 Morgantown, West Virginia 26505 February 15, 2017 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Protea Biosciences Group, Inc. Preliminary Proxy Statement on Schedule 14A Filed February 9, 2017, File No. 000-514 |
|
| February 15, 2017 |
PROTEA BIOSCIENCES GROUP, INC. Protea Biosciences Group, Inc. 1311 Pineview Drive, Suite 501 Morgantown, West Virginia 26505 February 15, 2017 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Protea Biosciences Group, Inc. Preliminary Proxy Statement on Schedule 14A Filed February 9, 2017 File No. 000-51474 To whom it may concern |
|
| February 9, 2017 |
Protea Biosciences Group PRELIMINARY PROXY STATEMENT PRE 14A 1 v458944pre14a.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| December 16, 2016 |
PROSPECTUS SUPPLEMENT NO. 6 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-202114 PROSPECTUS SUPPLEMENT NO. 6 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock This prospectus supplement no. 6 (the ?Supplement?) supplements information contained in the prospectus dated April 23, 2015 (the ?Prospectus?), prospectus supplement no. 1 dated May 18, 2015, prospectus supplement no. 2 dated August 28, 2015, pr |
|
| November 21, 2016 |
20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE DUE [_____________ __, 2017]1 EX-10.14 4 v452672ex10-14.htm EXHIBIT 10.14 Exhibit 10.14 Exhibit B NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT B |
|
| November 21, 2016 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.16 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR |
|
| November 21, 2016 |
EX-10.13 3 v452672ex10-13.htm EXHIBIT 10.13 Exhibit 10.13 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the “Company”), and the undersigned (the “Subscriber”). WITNESSETH: WHEREAS, the Company is conducting a private offering (the “Offering”) for which Laidlaw & Company (UK) L |
|
| November 21, 2016 |
Protea Biosciences Group, Inc. 1311 Pineview Drive, Suite 501 Morgantown, WV 26505 Exhibit 10.10 Protea Biosciences Group, Inc. 1311 Pineview Drive, Suite 501 Morgantown, WV 26505 September 9, 2016 To Investors in 20% OID Debentures and Warrants of Protea Biosciences Group, Inc. Dear Investor: In May, June, and July 2016, Protea Biosciences Group, Inc. (?Protea? or the ?Company?) sold to you and certain other accredited investors an aggregate of $2,013,750 principal amount of 20 |
|
| November 21, 2016 |
FORM OF COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.15 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| November 21, 2016 |
Protea Biosciences Group 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51474 Prote |
|
| November 15, 2016 |
Protea Biosciences Group NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-51474 CUSIP Number 74365B109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: September 30, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr |
|
| November 9, 2016 |
EX-10.1 2 v452532ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the “Company”), and the undersigned (the “Subscriber”). WITNESSETH: WHEREAS, the Company is conducting a private offering (the “Offering”) of up a minimum of $500,000 and up to |
|
| November 9, 2016 |
8-K 1 v4525328k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 27, 2016 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdict |
|
| November 9, 2016 |
FORM OF CLASS A COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 9, 2016 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR H |
|
| November 9, 2016 |
PROTEA BIOSCIENCES GROUP, INC. REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 PROTEA BIOSCIENCES GROUP, INC. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the ?Agreement?), dated as of the date set forth on the signature page hereto, is made by and between Protea Biosciences Group, Inc., a Delaware corporation (the ?Company?) and the undersigned investor (the ?Investor?). RECITALS WHEREAS, in connection with that certain Subscription Agreeme |
|
| November 9, 2016 |
FORM OF CLASS B COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2016 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 25, 2016 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF PROTEA BIOSCIENCES GROUP, INC. (a Delaware corporation) The undersigned, Stephen Turner, hereby certifies that: 1. He is the Chief Executive Officer of Protea Biosciences Group, Inc. (the ?Corporation?), a Delaware corporation, and is duly authorized by the unanimous written consent of the Board of Directors of the Corpora |
|
| September 23, 2016 |
Protea Biosciences Group DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant t |
|
| September 21, 2016 |
Protea Biosciences Group PRER14A PRER14A 1 v449124prer14a.htm PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 4 (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statemen |
|
| September 14, 2016 |
Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this ?Agreement?) is made as of September 8, 2016 (the ?Effective Date?) by and among (A) Protea Biosciences Group, Inc., a corporation organized under the laws of the State of Delaware (?PRGB? or the ?Parent?); (B) Protea Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the ?Subsidiary?); and (C) (the ?Sec |
|
| September 14, 2016 |
EX-10.5 6 v448841ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 Protea Biosciences, Inc. 1311 Pineview Dr, Suite 501 Morgantown, WV 26507 Greg W. Kilby 671 Kadar Drive | West Chester, PA 19382 | Phone: 484 868-6542 | [email protected] September 4th, 2016 Mr. Stephen Turner CEO & President Protea Biosciences, Inc. Dear Stephen, It is with extreme regret that I send you my notice of resignation as Protea's |
|
| September 14, 2016 |
EX-10.4 5 v448841ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 GUARANTY AGREEMENT This Guaranty (“Guaranty Agreement”) is made and executed as of this 8th day of September 2016 by PROTEA BIOSCIENCES, INC., a Delaware corporation (“Guarantor”), having its principal place of business at 1311 Pineview Drive, Suite 501, Morgantown, WV 26505, in favor of , (“Lender”), having its principal place of business at . |
|
| September 14, 2016 |
Exhibit 10.1 NOTE PURCHASE AGREEMENT NOTE PURCHASE AGREEMENT (this ?Agreement?) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the ?Company?), and the undersigned (the ?Lender?). WITNESSETH: WHEREAS, the Company desires to borrower the sum of $650,000 from the Lender and the Lender is willing to make a $650,000 loan to the Company (the ?Loan |
|
| September 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2016 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 14, 2016 |
10% ORIGINAL ISSUE DISCOUNT SECURED PROMISSORY NOTE DUE OCTOBER 15, 2016 EX-10.2 3 v448841ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE |
|
| September 13, 2016 |
Protea Biosciences Group PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 3 (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o |
|
| September 6, 2016 |
Protea Biosciences Group PRER14A PRER14A 1 v448380prer14a.htm PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 2 (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statemen |
|
| August 26, 2016 |
RW 1 v447791rw.htm RW Protea Biosciences Group, Inc. 1311 Pineview Drive. Suite 501 Morgantown, WV 26505 P: 304.292.2226 www.proteabio.com August 26, 2016 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Suzanne Hayes, Assistant Director Mr. Michael Gershon Mr. Joseph McCann Re: Protea Biosciences |
|
| August 22, 2016 |
Protea Biosciences Group PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 1 (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ |
|
| August 22, 2016 |
Protea Biosciences Group PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 1 (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ |
|
| August 18, 2016 |
Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF PROTEA BIOSCIENCES GROUP, INC. (a Delaware corporation) Adopted August 16, 2016 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 3 1.1 REGISTERED OFFICE 3 1.2 OTHER OFFICES 3 ARTICLE II - MEETINGS OF STOCKHOLDERS 3 2.1 PLACE OF MEETINGS 3 2.2 ANNUAL MEETING 3 2.3 SPECIAL MEETING 3 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEET |
|
| August 18, 2016 |
PRGB / Protea Biosciences Group Inc 10-Q/A - Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 16, 2016 |
Protea Biosciences Group PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Mate |
|
| August 16, 2016 |
Protea Biosciences Group PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Mate |
|
| August 15, 2016 |
PRGB / Protea Biosciences Group Inc 10-Q - Quarterly Report - 10-Q 10-Q 1 v44638510q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N |
|
| August 15, 2016 |
PRGB / Protea Biosciences Group Inc 10-Q - Quarterly Report - 10-Q 10-Q 1 v44638510q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N |
|
| August 15, 2016 |
Revised Media Advertising Agreement EX-10.2 4 v446385ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 Revised Media Advertising Agreement This Revised Agreement (the “Agreement”) is made this July 1, 2016 (the “Execution Date”), by and between AI & J Media INC. Located at 48 Wall Street, 11th Floor, New York, New York 10005 hereinafter sometimes referred to as Consultant and Protea Biosciences Group, Inc. located at 955 Hartman Run Road, Morgan |
|
| August 15, 2016 |
PROSPECTUS SUPPLEMENT NO. 5 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock 424B3 1 v447026424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-202114 PROSPECTUS SUPPLEMENT NO. 5 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock This prospectus supplement no. 5 (the “Supplement”) supplements information contained in the prospectus dated April 23, 2015 (the “Prospectus”), prospectus supplement no. 1 dated May 18, 2015, prospectus supplement |
|
| August 15, 2016 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PROTEA BIOSCIENCES GROUP, INC. (a Delaware corporation) Adopted June 22, 2016 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 3 2.5 |
|
| August 15, 2016 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. EX-10.1 3 v446385ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SO |
|
| August 15, 2016 |
PROSPECTUS SUPPLEMENT NO. 5 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock 424B3 1 v447026424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-202114 PROSPECTUS SUPPLEMENT NO. 5 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock This prospectus supplement no. 5 (the “Supplement”) supplements information contained in the prospectus dated April 23, 2015 (the “Prospectus”), prospectus supplement no. 1 dated May 18, 2015, prospectus supplement |
|
| August 15, 2016 |
Revised Media Advertising Agreement EX-10.2 4 v446385ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 Revised Media Advertising Agreement This Revised Agreement (the “Agreement”) is made this July 1, 2016 (the “Execution Date”), by and between AI & J Media INC. Located at 48 Wall Street, 11th Floor, New York, New York 10005 hereinafter sometimes referred to as Consultant and Protea Biosciences Group, Inc. located at 955 Hartman Run Road, Morgan |
|
| August 15, 2016 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. EX-10.1 3 v446385ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SO |
|
| August 12, 2016 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT (this ?Agreement?) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the ?Company?), and the undersigned (the ?Subscriber?). WITNESSETH: WHEREAS, the Company is conducting a private offering (the ?Offering?) for which Laidlaw & Company (UK) Ltd. is acting as placement agent on a ?best e |
|
| August 12, 2016 |
20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE DUE [______________, 2016] EX-10.2 3 v446732ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR S |
|
| August 12, 2016 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. EX-10.4 5 v446732ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SO |
|
| August 12, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2016 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2016 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT (this ?Agreement?) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the ?Company?), and the undersigned (the ?Subscriber?). WITNESSETH: WHEREAS, the Company is conducting a private offering (the ?Offering?) for which Laidlaw & Company (UK) Ltd. is acting as placement agent on a ?best e |
|
| August 12, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2016 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2016 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. EX-10.4 5 v446732ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SO |
|
| August 12, 2016 |
FORM OF COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| August 12, 2016 |
FORM OF COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 15, 2016 |
Protea Biosciences Group S-1/A As filed with the Securities and Exchange Commission on July 14, 2016 Registration No. |
|
| July 14, 2016 |
Protea Biosciences Group S-1/A S-1/A 1 v443740s1a.htm S-1/A As filed with the Securities and Exchange Commission on July , 2016 Registration No. 333-211674 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2903252 (State or Ot |
|
| June 22, 2016 |
Protea Biosciences Group FORM S-1/A As filed with the Securities and Exchange Commission on June 22, 2016 Registration No. |
|
| June 3, 2016 |
Protea Biosciences Group, Inc. Conflict Minerals Report For the Year Ended December 31, 2015 Exhibit 1.01 Protea Biosciences Group, Inc. Conflict Minerals Report For the Year Ended December 31, 2015 This Conflict Minerals Report of Protea Biosciences Group, Inc. (the ?Company?) for the year ended December 31, 2015 is in accordance with Rule 13p-1 (the ?Rule?) under the Securities Exchange Act of 1934 (the ?1934 Act?). The Rule was adopted by the Securities and Exchange Commission (the ?SE |
|
| June 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 1311 Pineview Drive, Suite 501, Morgantown, WV 26505 |
|
| May 27, 2016 |
Protea Biosciences Group FORM S-1 As filed with the Securities and Exchange Commission on May 27, 2016 Registration No. |
|
| May 13, 2016 |
EX-10.7 5 v439235ex10-7.htm EXHIBIT 10.7 Exhibit 10.7 Media Advertising Agreement This Agreement (the “Agreement”) is made this March 16, 2016 (the “Execution Date”), by and between Al & J Media INC. Located at 48 Wall Street, 11th Floor, New York, New York 10005 hereinafter sometimes referred to as Consultant and Protea Biosciences Group, Inc. located at 1311 Pineview Drive, Suite 501, Morgantown |
|
| May 13, 2016 |
Protea Biosciences Group 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51474 Protea Bi |
|
| May 13, 2016 |
LOAN MODIFICATION AND WARRANT ISSUANCE AGREEMENT Exhibit 10.4 LOAN MODIFICATION AND WARRANT ISSUANCE AGREEMENT THIS LOAN MODIFICATION AND WARRANT ISSUANCE AGREEMENT (this ?Agreement?) made and entered on this 30 day of December, 2015, by and between PROTEA BIOSCIENCES GROUP, INC. (the ?Company?), a corporation existing under the laws of the State of Delaware, and WEST VIRGINIA JOBS INVESTMENT TRUST BOARD (?WVJITB?); WHEREAS, WVJITB loaned $400,0 |
|
| May 13, 2016 |
PROTEA BIOSCIENCES GROUP, INC. TO PURCHASE COMMON STOCK OF THE COMPANY Exhibit 10.5 THIS WARRANT AND THE SECURITIES UNDERLYING THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS AND THE RULES AND REGULATIONS THE |
|
| May 13, 2016 |
LOAN MODIFICATION AND WARRANT ISSUANCE AGREEMENT Exhibit 10.6 LOAN MODIFICATION AND WARRANT ISSUANCE AGREEMENT THIS LOAN MODIFICATION AND WARRANT ISSUANCE AGREEMENT (this ?Agreement?) made and entered on this 31st day of March, 2016, by and between PROTEA BIOSCIENCES GROUP, INC. (the ?Company?), a corporation existing under the laws of the State of Delaware, and WEST VIRGINIA JOBS INVESTMENT TRUST BOARD (?WVJITB?); WHEREAS, WVJITB loaned $400,00 |
|
| March 28, 2016 |
PROSPECTUS SUPPLEMENT NO. 4 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock 424B3 1 v435492424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-202114 PROSPECTUS SUPPLEMENT NO. 4 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock This prospectus supplement no. 4 (the “Supplement”) supplements information contained in the prospectus dated April 23, 2015 (the “Prospectus”), prospectus supplement no. 1 dated May 18, 2015, prospectus supplement |
|
| March 16, 2016 |
Protea Biosciences Group FORM 10-K (Annual Report) 10-K 1 v43219510k.htm FORM 10-K United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual report under section 13 0r 15(d) of the securities exchange act of 1934 For the fiscal year ended December 31, 2015 or ¨ transition report under section 13 0r 15(d) of the securities exchange act of 1934 For the transition period from to Commission file number 000-51474 PROTEA |
|
| March 16, 2016 |
Exhibit 10.96 FORM OF LOCK-UP AGREEMENT August 27, 2015 Re: Unit Purchase Agreement, dated as of August 27, 2015 (the “Purchase Agreement”), between Protea Biosciences Group, Inc., a Delaware corporation (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (t |
|
| March 16, 2016 |
EX-21.1 3 v432195ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARY OF THE COMPANY Protea Biosciences, Inc. (Delaware Corporation) |
|
| March 10, 2016 |
Protea Biosciences Group FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2016 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2016 |
PROTEA BIOSCIENCES GROUP, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK EX-10.3 4 v433954ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 THIS WARRANT AND THE COMMON STOCK ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE HEREUNDER MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT OR ANY SHARES ISSUABLE HEREUNDER UNDE |
|
| March 10, 2016 |
Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE Effective Date: March 4, 2016 U.S. $655,000.00 FOR VALUE RECEIVED, Protea Biosciences Group, Inc., a Delaware corporation (“Borrower”), promises to pay to St. George Investments LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $655,000.00 and any interest, fees, charges, and late fees on the date that is six (6) months after t |
|
| March 10, 2016 |
EX-10.1 2 v433954ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of March 4, 2016, is entered into by and between Protea Biosciences Group, Inc., a Delaware corporation (“Company”), and St. George Investments LLC, a Utah company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and d |
|
| December 8, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2015 Protea Biosciences Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 24, 2015 |
PROSPECTUS SUPPLEMENT NO. 3 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock 424B3 1 v425591424b3.htm FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-202114 PROSPECTUS SUPPLEMENT NO. 3 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock This prospectus supplement no. 3 (the “Supplement”) supplements information contained in the prospectus dated April 23, 2015 (the “Prospectus”), prospectus supplement no. 1 dated May 18, 2015 and prospectus sup |
|
| October 14, 2015 |
Protea Biosciences Group DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Mate |
|
| September 23, 2015 |
CORRESP 1 filename1.htm Protea Biosciences Group, Inc. 1311 Pineview Drive. Suite Morgantown, WV 26505 P: 304.292.2226 www.proteabio.com September 21, 2015 VIA EDGAR AND FEDERAL EXPRESS Division of Corporation Finance Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Ms. Suzanne Hayes, Assistant Director Mr. Johnny Gharib Re: Protea Biosciences Group, Inc. Preli |
|
| September 23, 2015 |
Protea Biosciences Group PRER14A PRER14A 1 v420776prer14a.htm PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Ad |
|
| September 11, 2015 |
CORRESP 1 filename1.htm Protea Biosciences Group, Inc. 1311 Pineview Drive. Suite Morgantown, WV 26505 P: 304.292.2226 www.proteabio.com September 11, 2015 VIA EDGAR AND FEDERAL EXPRESS Division of Corporation Finance Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Ms. Suzanne Hayes, Assistant Director Mr. Johnny Gharib Re: Protea Biosciences Group, Inc. Preli |
|
| September 1, 2015 |
Protea Biosciences Group PRE 14A PRE 14A 1 v419549pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Add |
|
| August 28, 2015 |
PROSPECTUS SUPPLEMENT NO. 2 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-202114 PROSPECTUS SUPPLEMENT NO. 2 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock This prospectus supplement no. 2 (the “Supplement”) supplements information contained in the prospectus dated April 23, 2015 (the “Prospectus”) and prospectus supplement no. 1 dated May 18, 2015, relating to the resale by selling stockholders of |
|
| July 8, 2015 |
Exhibit 3.01 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF PROTEA BIOSCIENCES GROUP, INC. (a Delaware corporation) The undersigned, Stephen Turner, hereby certifies that: 1. He is the Chief Executive Officer of Protea Biosciences Group, Inc. (the ?Corporation?), a Delaware corporation, and is duly authorized by the unanimous written consent of the Board of Directors of the Corpor |
|
| July 8, 2015 |
8-K 1 v4150968k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2015 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction |
|
| May 29, 2015 |
20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE DUE NOVEMBER 22, 2015 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| May 29, 2015 |
FORM OF COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 29, 2015 |
EX-10.1 2 v411944ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc., (the “Company”), and the undersigned (the “Subscriber”). WITNESSETH: WHEREAS, the Company is conducting a private offering (the “Offering”) for which Laidlaw & Company (UK) Ltd. |
|
| May 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2015 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 955 Hartman Run Road Morgantown, WV 26505 (Address o |
|
| May 28, 2015 |
Protea Biosciences Group, Inc. Conflict Minerals Report For the Year Ended December 31, 2014 Exhibit 1.01 Protea Biosciences Group, Inc. Conflict Minerals Report For the Year Ended December 31, 2014 This Conflict Minerals Report of Protea Biosciences Group, Inc. (the ?Company?) for the year ended December 31, 2014 is in accordance with Rule 13p-1 (the ?Rule?) under the Securities Exchange Act of 1934 (the ?1934 Act?). The Rule was adopted by the Securities and Exchange Commission (the ?SE |
|
| May 18, 2015 |
PROSPECTUS SUPPLEMENT NO. 1 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-202114 PROSPECTUS SUPPLEMENT NO. 1 PROTEA BIOSCIENCES GROUP, INC. 48,221,763 Shares of Common Stock This prospectus supplement no. 1 (the ?Supplement?) supplements information contained in the prospectus dated April 23, 2015 (the ?Prospectus?), relating to the resale by selling stockholders of Protea Biosciences Group, Inc., a Delaware corporat |
|
| May 1, 2015 |
PROSPECTUS Protea Biosciences Group, Inc. 48,221,763 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) File Number 333-202114 PROSPECTUS Protea Biosciences Group, Inc. |
|
| April 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2015 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 17, 2015 |
Protea Biosciences Group S-1/A S-1/A 1 v407516s1a.htm S-1/A As filed with the Securities and Exchange Commission on April 17, 2015 Registration No. 333-202114 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Protea Biosciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 20-2903252 (St |
|
| April 16, 2015 |
Protea Biosciences Group FORM S-1/A As filed with the Securities and Exchange Commission on April 16, 2015 Registration No. |
|
| April 8, 2015 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 8 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Steve Antoline 955 Hartman Run Road Morgantown, WV 26505 (304) 292-2226 (Name, Address and Telephone Number of |
|
| April 6, 2015 |
PROTEA BIOSCIENCES GROUP, INC. REGISTRATION RIGHTS AGREEMENT EX-10.3 4 v403988ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 PROTEA BIOSCIENCES GROUP, INC. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”), dated as of the date set forth on the signature page hereto, is made by and between Protea Biosciences Group, Inc., a Delaware corporation (the “Company”) and the undersigned investor (the “Investor”). RECITALS WHEREAS, in connecti |
|
| April 6, 2015 |
Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Stephen Turner (the ?Executive?) and Protea Biosciences Group, Inc., a corporation organized under the laws of Delaware (the ?Company?). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREAS, the Executive desires to be emplo |
|
| April 6, 2015 |
UNIT PURCHASE AGREEMENT BY AND AMONG PROTEA BIOSCIENCES GROUP, INC. AND THE PURCHASERS PARTY HERETO EX-10.2 3 v403988ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 UNIT PURCHASE AGREEMENT BY AND AMONG PROTEA BIOSCIENCES GROUP, INC. AND THE PURCHASERS PARTY HERETO Schedules and Exhibits TO Unit PURCHASE AGREEMENT Schedule 3.1 Foreign Jurisdictions Schedule 3.2 Subsidiaries; Joint Ventures, Partnerships Schedule 3.3.2 Capitalization Matters Schedule 3.4 Authorization; Binding Obligations Schedule 3.6 Absenc |
|
| April 6, 2015 |
Exhibit 3.01 CERTIFICATE OF DESIGNATIONS OF THE SERIES A CONVERTIBLE REDEEMABLE PREFERRED STOCK OF PROTEA BIOSCIENCES GROUP, INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW I, Stephen Turner, hereby certify that I am the President of Protea Biosciences Group, Inc. (the ?Corporation?), a corporation organized and existing under the Delaware General Corporation Law (the ?DGCL?), |
|
| April 6, 2015 |
Protea Biosciences Group FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2015 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2015 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 6, 2015 |
EXHIBIT 10.1 Execution Copy SHARE PURCHASE AGREEMENT among PROTEA BIOSCIENCES GROUP, INC. vivoPHARM PTY LTD. DR. RALF BRANDT and THE BRANDT FAMILY TRUST SOUTH AUSTRALIAN LIFE SCIENCE ADVANCEMENT PARTNERSHIP, LP TERRA ROSSA CAPITAL PTY LTD ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY trading as ?RMIT UNIVERSITY? Dated as of March 31, 2015 TABLE OF CONTENTS SECTION PAGE ARTICLE I DEFINITIONS 1.1. Definit |
|
| April 6, 2015 |
EX-10.1 2 v403988ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 To subscribe for Units including Preferred Stock and Warrants to Purchase Shares of Common Stock in the private offering of PROTEA BIOSCIENCES GROUP, INC. 1. Date and Fill in the number of units (each unit consisting of (a) 50,000 shares of Series A Convertible Preferred Stock, par value $0.0001 per share, of the Company (“Preferred Stock”), an |
|
| April 6, 2015 |
Exhibit 99.1 Protea Biosciences Group, Inc. 955 Hartman Run Road Morgantown, WV 26507 P: 304.292.2226 F: 304.292.7101 www.proteabio.com NEWS RELEASE FOR IMMEDIATE RELEASE Protea announces agreement to acquire vivoPharm Combined company to develop and market new services for pharmaceutical R&D Morgantown WV; 8:00 AM ET April 6, 2015 – Protea Biosciences Group, Inc. (OTCQB: PRGB) (“Protea”) announce |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2015 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 27, 2015 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 7 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Steve Antoline 955 Hartman Run Road Morgantown, WV 26505 (304) 292-2226 (Name, Address and Telephone Number of |
|
| March 18, 2015 |
CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATIONS PROTEA BIOSCIENCES GROUP, INC. EX-3.01 2 v404923ex3-01.htm EXHIBIT 3.01 Exhibit 3.01 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATIONS OF PROTEA BIOSCIENCES GROUP, INC. PROTEA BIOSCIENCES GROUP, INC. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY that: FIRST: The Corporation filed with the Secretary of State of the |
|
| March 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2015 PROTEA BIOSCIENCES GROUP, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51474 20-2903252 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 13, 2015 |
Exhibit 10.7 |
|
| February 13, 2015 |
PRGB / Protea Biosciences Group Inc S-1 - Registration Statement - FORM S-1 S-1 1 v401637s1.htm FORM S-1 As filed with the Securities and Exchange Commission on February 13, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Protea Biosciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 20-2903252 (State or Other Jurisdictio |
|
| February 13, 2015 |
EX-10.6 3 v401637ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 |
|
| February 13, 2015 |
Exhibit 21.1 SUBSIDIARY OF THE REGISTRANT Protea Biosciences, Inc. (Delaware Corporation) |
|
| February 13, 2015 |
FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC. Exhibit 10.88 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR |
|
| January 5, 2015 |
8-K 1 v3979958k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2015 (December 31, 2014) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (S |
|
| December 19, 2014 |
8-K 1 v3971118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 (December 18, 2014) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 |
|
| December 17, 2014 |
PRGB / Protea Biosciences Group Inc POS AM - - POS AM As filed with the Securities and Exchange Commission on December 17, 2014 Registration Statement No. |
|
| December 5, 2014 |
Submission of Matters to a Vote of Security Holders 8-K 1 v3959848-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2014 (December 1, 2014) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 ( |
|
| November 28, 2014 |
8-K 1 v3953118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2014 (November 25, 2014) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 |
|
| November 18, 2014 |
8-K 1 v3947498-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2014 (November 18, 2014) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 |
|
| November 18, 2014 |
Protea Biosciences Announces 2014 Third Quarter Financial Results Exhibit 99.1 Protea Biosciences Group, Inc. 955 Hartman Run Road Morgantown, WV 26507 P: 304.292.2226 F: 304.292.7101 www.proteabio.com NEWS RELEASE DRAFT - NOT FOR IMMEDIATE RELEASE Protea Biosciences Announces 2014 Third Quarter Financial Results Morgantown, WV; 8:30 AM ET November 18, 2014 – Protea Biosciences Group, Inc. (OTCQB: PRGB) (“Protea” or the “Company”) announced today that it has rep |
|
| November 5, 2014 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 05:02 PM 10/30/2014 FILED 04:21 PM 10/30/2014 SRV 141354675 – 397450 FILE CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF PROTEA BIOSCIENCES GROUP, INC. The undersigned DOES HEREBY CERTIFY that the following resolution was duly adopted by the Board of Dire |
|
| November 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2014 (October 30, 2014) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of |
|
| October 29, 2014 |
PRGB / Protea Biosciences Group Inc DEF 14A - - DEF 14A DEF 14A 1 v392106def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Solicitation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Consent Solicitation Statement ¨ Confidential, for Use of the Commissio |
|
| October 1, 2014 |
PRGB / Protea Biosciences Group Inc PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Solicitation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Consent Solicitation Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| September 29, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 6 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26505 (304) 292-2226 (Name, Address and Telephone Number o |
|
| September 12, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 13 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number |
|
| September 8, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SCHEDULE 13D/A Activist Investment SC 13D/A 1 v388641sc13d-a.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 5 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26505 (304) 2 |
|
| August 25, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 4 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26505 (304) 292-2226 (Name, Address and Telephone Number o |
|
| August 19, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 12 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number |
|
| August 18, 2014 |
August 18, 2014 Stephen Turner Chairman of the Board Protea BioSciences 955 Hartman Run Rd. |
|
| August 18, 2014 |
8-K 1 v3871688k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2014 PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisd |
|
| August 5, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 3 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26505 (304) 292-2226 (Name, Address and Telephone Number o |
|
| July 15, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 11 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number |
|
| July 10, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 2 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26505 (304) 292-2226 (Name, Address and Telephone Number o |
|
| July 3, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment SC 13D/A 1 v383261sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 10 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-22 |
|
| June 19, 2014 |
8-K 1 v3818768k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2014 PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdic |
|
| June 9, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 9 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 74365B109 (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number |
|
| June 4, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 8 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Pe |
|
| May 30, 2014 |
Protea Biosciences Group, Inc. Conflict Minerals Report For the Year Ended December 31, 2013 Exhibit 1.02 Protea Biosciences Group, Inc. Conflict Minerals Report For the Year Ended December 31, 2013 This Conflict Minerals Report of Protea Biosciences Group, Inc. (the “Company”) for the year ended December 31, 2013 is in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). The Rule was adopted by the Securities and Exchange Commission (SEC) |
|
| May 30, 2014 |
SD 1 v380272sd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 955 Hartman Run Road Morgantow |
|
| May 28, 2014 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 v3799848k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2014 PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction o |
|
| May 16, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 7 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Pe |
|
| May 13, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 6 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Pe |
|
| April 11, 2014 |
April 11, 2014 Richardson & Patel, LLP The Chrysler Building 405 Lexington Avenue, 49th Floor New York, NY 10174 Attn: David N. |
|
| April 11, 2014 |
S-8 1 v374451s8.htm FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Protea Biosciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 99-0370904 (State or other jurisdiction of (IRS Employee Identification No.) incorporation or organization) 955 Hartman Run Road Morgantown |
|
| April 7, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Person Authorized to |
|
| April 7, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Person Authorized t |
|
| April 7, 2014 |
PROSPECTUS PROTEA BIOSCIENCES GROUP, INC. 43,210,440 shares of Common Stock Filed Pursuant to Rule 424(b)(3) File Number 333-193331 PROSPECTUS PROTEA BIOSCIENCES GROUP, INC. |
|
| April 4, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment SC 13D/A 1 v374035sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 5 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Na |
|
| March 31, 2014 |
Protea Biosciences Group FORM 10-K (Annual Report) United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K T Annual report under section 13 0r 15(d) of the securities exchange act of 1934 For the fiscal year ended December 31, 2013 ¨ transition report under section 13 0r 15(d) of the securities exchange act of 1934 For the transition period from Commission file number 000-51474 PROTEA BIOSCIENCES GROUP, INC. (Name of regi |
|
| March 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2014 (March 19, 2014) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of inc |
|
| February 14, 2014 |
PRGB / Protea Biosciences Group Inc / ANTOLINE STEVE - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Steven Antoline 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Person Authorized to |
|
| February 14, 2014 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 4 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Pe |
|
| February 14, 2014 |
PRGB / Protea Biosciences Group Inc / HOSTLER STANLEY - SC 13D Activist Investment SC 13D 1 v368374sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Stanley Hostler 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephon |
|
| February 3, 2014 |
CORRESP 1 filename1.htm Protea Biosciences Group, Inc. 955 Hartman Run Road Morgantown, WV 26507 P: 304.292.2226 F: 304.292.7101 www.proteabio.com January 29, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Protea Biosciences Group, Inc. Registration Statement on Form S-1 Filed January 13, 2014 File No. 333 |
|
| January 29, 2014 |
As filed with the Securities and Exchange Commission on January 29, 2014 Registration Statement No. |
|
| January 29, 2014 |
Protea Biosciences Group, Inc. 955 Hartman Run Road Morgantown, WV 26507 P: 304.292.2226 F: 304.292.7101 www.proteabio.com January 29, 2014 VIA EDGAR Jeffrey P. Riedler, Assistant Director United States Securities and Exchange Commission Washington, D.C. 20549 Re: Protea Biosciences Group, Inc. Registration Statement on Form S-1 Filed January 13, 2014 File No. 333-193331 Dear Mr. Riedler: This let |
|
| January 29, 2014 |
CORRESP 1 filename1.htm Protea Biosciences Group, Inc. 955 Hartman Run Road Morgantown, WV 26507 P: 304.292.2226 F: 304.292.7101 www.proteabio.com January 29, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Protea Biosciences Group, Inc. Registration Statement on Form S-1 Filed January 13, 2014 File No. 333 |
|
| January 13, 2014 |
As filed with the Securities and Exchange Commission on January 13, 2014 Registration Statement No. |
|
| December 31, 2013 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2013 (December 30, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction |
|
| December 20, 2013 |
EX-16.1 2 v363580ex16-1.htm EX-16.1 EXHIBIT 16.1 December 19, 2013 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Protea Biosciences Group, Inc.’s Form 8-K dated December 20, 2013 and are in agreement with the statements contained therein to the extent they relate to our firm. We have no basis to agree or disagree with ot |
|
| December 20, 2013 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2013 (December 17, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction |
|
| December 11, 2013 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2013 (December 10, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction |
|
| December 2, 2013 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 2, 2013 (November 27, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction o |
|
| November 19, 2013 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2013 (November 18, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction |
|
| November 19, 2013 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2013 (November 1, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or ot |
|
| November 4, 2013 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2013 (November 1, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of |
|
| October 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2013 (October 25, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of |
|
| October 30, 2013 |
EX-10.1 2 v358711ex10-1.htm EX-10.1 Note Purchase Agreement This Note Purchase Agreement (the “Agreement”) is made as of the latest date set forth on the signature page hereto (the “Effective Date”) by and among Protea Biosciences Group, Inc., a Delaware corporation (the “Company”), and the undersigned purchaser (each, individually, a “Purchaser”, and collectively, the “Purchasers”). Any capitaliz |
|
| October 30, 2013 |
PROTEA BIOSCIENCES GROUP, Inc. CONVERTIBLE PROMISSORY NOTE EX-10.2 3 v358711ex10-2.htm EX-10.2 THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), APPLICABLE STATE SECURITIES LAWS, OR APPLICABLE LAWS OF ANY FOREIGN JURISDICTION. THIS NOTE AND SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DIS |
|
| October 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2013 (October 7, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of |
|
| October 1, 2013 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 3 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Pe |
|
| September 24, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 24, 2013 (September 20, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdictio |
|
| September 17, 2013 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 1 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Pe |
|
| September 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 16, 2013 (September 11, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdictio |
|
| August 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): August 7, 2013 PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of incorporation or org |
|
| August 12, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2013 (August 6, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of in |
|
| August 12, 2013 |
PROTEA BIOSCIENCES GROUP, INC. CONVERTIBLE PROMISSORY NOTE ADDENDUM NO. 3 PROTEA BIOSCIENCES GROUP, INC. CONVERTIBLE PROMISSORY NOTE ADDENDUM NO. 3 $20,000 Issue Date: August 6, 2013 This addendum is to acknowledge the fact that Stephen and Nancy Turner, by signing below, have agreed to extend the maturity date of the Convertible Promissory Note issued by Protea Biosciences Group, Inc., a Delaware corporation (the "Company"), for the sum of $20,000 on September 25, 2012 |
|
| August 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2013 (July 29, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of inco |
|
| July 23, 2013 |
PROTEA BIOSCIENCES GROUP, INC. TO PURCHASE COMMON STOCK OF THE COMPANY EX-10.2 3 v350659ex10-2.htm EX-10.2 THIS WARRANT AND THE SECURITIES UNDERLYING THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS |
|
| July 23, 2013 |
CONVERSION AGREEMENT THIS CONVERSION AGREEMENT (the "Agreement"), dated as of 2013, by and among, Protea Biosciences Group, Inc. |
|
| July 23, 2013 |
Note and Warrant Purchase Agreement Note and Warrant Purchase Agreement This Note and Warrant Purchase Agreement (the “Agreement”) is made as of , 2013 (the “Effective Date”) by and among Protea Biosciences Group, Inc. |
|
| July 23, 2013 |
PROTEA BIOSCIENCES GROUP, INC. TO PURCHASE COMMON STOCK OF THE COMPANY EX-10.5 6 v350659ex10-5.htm EX-10.5 THIS WARRANT AND THE SECURITIES UNDERLYING THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS |
|
| July 23, 2013 |
THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), APPLICABLE STATE SECURITIES LAWS, OR APPLICABLE LAWS OF ANY FOREIGN JURISDICTION. |
|
| July 23, 2013 |
8-K 1 v3506598k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 23, 2013 (July 17, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or oth |
|
| June 24, 2013 |
8-K 1 v3485138k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 24, 2013 (June 18, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State o |
|
| June 24, 2013 |
STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Protea Biosciences Group, Inc. |
|
| June 14, 2013 |
PRGB / Protea Biosciences Group Inc / AUSTIN JOSIAH T - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 1 Under the Securities Exchange Act of 1934 Protea Biosciences Group, Inc. (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) None (CUSIP Number) Josiah T. Austin 955 Hartman Run Road Morgantown, WV 26507 (304) 292-2226 (Name, Address and Telephone Number of Pe |
|
| June 4, 2013 |
DEF 14A 1 v346698def14a.htm SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by R |
|
| May 24, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant T Filed by a Party other than the Registrant ¨ Check the appropriate box: T Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 15, 2013 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 15, 2013 (April 2, 2013) PROTEA BIOSCIENCES GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-51474 20-2903252 (State or other jurisdiction of inco |
